$ONCT
Oncternal Therapeutics Inc

2021 Q2 Form 10-Q Financial Statement

#000156459021041698 Filed on August 05, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $883.0K $623.0K $578.0K
YoY Change 41.73% -7.01% 22.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.381M $2.340M $2.630M
YoY Change 44.49% 44.44% 182.8%
% of Gross Profit
Research & Development $0.00 $0.00 $0.00
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $0.00 $6.158M $5.329M
YoY Change -100.0% -72.38% 88.44%
Operating Profit -$7.690M -$5.535M -$4.751M
YoY Change 38.93% -74.4% 101.48%
Interest Expense $8.000K $0.00 $10.00K
YoY Change -100.0% -80.0%
% of Operating Profit
Other Income/Expense, Net $0.00 $13.00K
YoY Change -100.0% -79.69%
Pretax Income -$7.682M -$5.540M -$4.740M
YoY Change 38.66% -75.75% 106.99%
Income Tax
% Of Pretax Income
Net Earnings -$7.682M -$5.535M -$4.738M
YoY Change 38.79% -75.77% 106.54%
Net Earnings / Revenue -869.99% -888.44% -819.72%
Basic Earnings Per Share
Diluted Earnings Per Share -$155.6K -$341.1K -$308.6K
COMMON SHARES
Basic Shares Outstanding 15.39M 15.39M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $103.7M $16.60M $16.00M
YoY Change 524.48% -41.75% -24.53%
Cash & Equivalents $103.7M $16.60M $16.02M
Short-Term Investments
Other Short-Term Assets $3.936M $1.400M $500.0K
YoY Change 181.14% 0.0% -61.54%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $107.6M $18.00M $16.56M
YoY Change 497.77% -39.74% -26.38%
LONG-TERM ASSETS
Property, Plant & Equipment $162.0K $100.0K $200.0K
YoY Change 62.0% -66.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $658.0K $800.0K $1.047M
YoY Change -17.75% 4.3%
Total Long-Term Assets $820.0K $900.0K $1.201M
YoY Change -8.89% -12.79% 1101.0%
TOTAL ASSETS
Total Short-Term Assets $107.6M $18.00M $16.56M
Total Long-Term Assets $820.0K $900.0K $1.201M
Total Assets $108.4M $18.90M $17.77M
YoY Change 473.65% -38.84% -21.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.009M $1.500M $1.376M
YoY Change -32.73% -45.75% 129.33%
Accrued Expenses $2.493M $3.607M $2.778M
YoY Change -30.88% 41.45% 131.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.900M $9.000M $7.317M
YoY Change -34.44% 14.78% 306.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $300.0K $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $100.0K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $300.0K $100.0K
YoY Change -100.0% 200.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.900M $9.000M $7.317M
Total Long-Term Liabilities $0.00 $300.0K $100.0K
Total Liabilities $5.900M $9.300M $7.400M
YoY Change -36.56% 16.25% 311.11%
SHAREHOLDERS EQUITY
Retained Earnings -$96.40M -$75.80M -$70.31M
YoY Change 27.18% 34.1%
Common Stock $15.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $102.5M $9.598M $10.40M
YoY Change
Total Liabilities & Shareholders Equity $108.4M $18.90M $17.77M
YoY Change 473.65% -38.84% -21.39%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income -$7.682M -$5.535M -$4.738M
YoY Change 38.79% -75.77% 106.54%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$7.603M -$4.220M -$4.036M
YoY Change 80.17% -32.37% 11.09%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 59.00K 4.820M 4.000K
YoY Change -98.78% 100.0%
NET CHANGE
Cash From Operating Activities -7.603M -4.220M -4.036M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 59.00K 4.820M 4.000K
Net Change In Cash -7.544M 600.0K -4.032M
YoY Change -1357.33% -94.82% 8.68%
FREE CASH FLOW
Cash From Operating Activities -$7.603M -$4.220M -$4.036M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y4M24D
CY2021Q2 onct Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash
AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash
4000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M24D
CY2021Q2 onct Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
2000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
102519000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
10395000
CY2020Q2 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
602000
CY2020Q2 onct Issuance Of Common Stock And Warrants Net Of Issuance Costs
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
4392000
CY2020Q2 onct Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
3000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-5535000
CY2020 onct Class Of Warrant Weighted Average Remaining Contractual Term
ClassOfWarrantWeightedAverageRemainingContractualTerm
P4Y4M24D
onct Warrant Weighted Average Remaining Contractual Term Exercised
WarrantWeightedAverageRemainingContractualTermExercised
P4Y4M2D
onct Class Of Warrant Weighted Average Remaining Contractual Term
ClassOfWarrantWeightedAverageRemainingContractualTerm
P3Y9M29D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M18D
onct Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-82000
onct Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-73000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
126000
onct Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
238000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
108303000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
56000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
112951000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
414000
onct Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash
AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash
105000
onct Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
5000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2674000
us-gaap Net Income Loss
NetIncomeLoss
-13630000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
14312000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
602000
onct Issuance Of Common Stock And Warrants Net Of Issuance Costs
IssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
4392000
onct Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability
AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
6000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
742000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
415000
us-gaap Net Income Loss
NetIncomeLoss
-10273000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49385000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Revenues
Revenues
883000
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49385000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48802000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48802000
us-gaap Operating Expenses
OperatingExpenses
15279000
CY2020Q2 us-gaap Revenues
Revenues
623000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3381000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2343000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5535000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-5535000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7690000
us-gaap Operating Income Loss
OperatingIncomeLoss
-13648000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
103663000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
8000
us-gaap Investment Income Interest
InvestmentIncomeInterest
18000
us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
us-gaap Net Income Loss
NetIncomeLoss
-13630000
us-gaap Net Income Loss
NetIncomeLoss
-10273000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49364
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16241
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49230
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15798
us-gaap Profit Loss
ProfitLoss
-13630000
us-gaap Profit Loss
ProfitLoss
-10273000
us-gaap Share Based Compensation
ShareBasedCompensation
2674000
us-gaap Share Based Compensation
ShareBasedCompensation
742000
onct Noncash Lease Expense
NoncashLeaseExpense
82000
onct Noncash Lease Expense
NoncashLeaseExpense
73000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2562000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
662000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-134000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
494000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-544000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1275000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
603000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
167000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13593000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8257000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
301000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
414000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4518000
onct Proceeds From Stock Options Exercised And Warrant Exercises1
ProceedsFromStockOptionsExercisedAndWarrantExercises1
105000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
519000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4823000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13074000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3434000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16617000
onct Cashless Exercise Of Warrants
CashlessExerciseOfWarrants
1836000
us-gaap Stock Issued1
StockIssued1
415000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
102519000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.003
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.008
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.891
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.917
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.896
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
343000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2674000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103700000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-96400000
CY2021Q2 onct Accrued Clinical Trials
AccruedClinicalTrials
600000
CY2021Q2 us-gaap Deferred Revenue
DeferredRevenue
2200000
CY2020Q4 us-gaap Deferred Revenue
DeferredRevenue
1600000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
8000
CY2020Q2 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
27000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
11000
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
30000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9424
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4146
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
CY2021Q2 onct Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
723000
CY2020Q4 onct Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
412000
CY2021Q2 onct Accrued Clinical Trials
AccruedClinicalTrials
594000
CY2020Q4 onct Accrued Clinical Trials
AccruedClinicalTrials
980000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
182000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
77000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
988000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1528000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
45000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2493000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3042000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
92000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
77000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
169000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
162000
CY2021Q2 us-gaap General Insurance Expense
GeneralInsuranceExpense
1800000
us-gaap General Insurance Expense
GeneralInsuranceExpense
1800000
us-gaap General Insurance Expense
GeneralInsuranceExpense
1400000
CY2020Q2 us-gaap General Insurance Expense
GeneralInsuranceExpense
1400000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0
CY2020Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
5031841
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.25
onct Exercise Of Warrants
ExerciseOfWarrants
754958
onct Warrant Exercised Price Per Share
WarrantExercisedPricePerShare
2.57
CY2021Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
4276883
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.42
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5140153
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.53
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2250390000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5140153
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
5.53
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
2250390000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1205130
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.67
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1760058000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2107625
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3483900
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.38
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
345209
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.81
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
106163
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.89
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5140153
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.53
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.008
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.899
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1836000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
742000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
16100000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P3Y4M24D
CY2021Q2 onct Common Stock Warrants Reserved For Future Issuance
CommonStockWarrantsReservedForFutureIssuance
4277000
CY2021Q2 onct Common Stock Options Issued And Outstanding For Future Issuance
CommonStockOptionsIssuedAndOutstandingForFutureIssuance
5140000
CY2021Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11818000

Files In Submission

Name View Source Status
0001564590-21-041698-index-headers.html Edgar Link pending
0001564590-21-041698-index.html Edgar Link pending
0001564590-21-041698.txt Edgar Link pending
0001564590-21-041698-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
onct-10q_20210630.htm Edgar Link pending
onct-10q_20210630_htm.xml Edgar Link completed
onct-20210630.xsd Edgar Link pending
onct-20210630_cal.xml Edgar Link unprocessable
onct-20210630_def.xml Edgar Link unprocessable
onct-20210630_lab.xml Edgar Link unprocessable
onct-20210630_pre.xml Edgar Link unprocessable
onct-ex101_51.htm Edgar Link pending
onct-ex102_52.htm Edgar Link pending
onct-ex103_49.htm Edgar Link pending
onct-ex311_12.htm Edgar Link pending
onct-ex312_7.htm Edgar Link pending
onct-ex321_11.htm Edgar Link pending
onct-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending